tbuckley/cabot-search huggingface dataset:
Expression of HER2/<i>erb</i>B-2 Correlates With Survival in Osteosarcoma
Authors: Richard Gorlick, Andrew G. Huvos, Glenn Heller, Alex Aledo, G. Peter Beardsley, John H. Healey, Paul A. Meyers
Journal: Journal of Clinical Oncology (1999)

In osteosarcoma, prognostic factors at diagnosis other than clinical stage have not been clearly identified. The aim of this study was to determine whether human epidermal growth factor receptor 2 (HER2)/erbB-2, p-glycoprotein, or p53 expression correlated with histologic response to preoperative chemotherapy or event-free survival.We performed a retrospective immunohistochemical study on material obtained from patients treated on the Memorial Sloan-Kettering Cancer Center T12 protocol between 1986 and 1993. Paraffin-embedded tissue was identified from 53 patients (73% of patients enrolled onto protocol) and stained for HER2/erbB-2, p53, and p-glycoprotein expression using standard monoclonal antibodies and methods.At the time of initial biopsy, 20 (42.6%) of 47 samples demonstrated high levels of HER2/erbB-2 expression. Higher frequencies of expression were observed in samples from patients with metastatic disease at presentation and at the time of relapse. Expression of HER2/erbB-2 correlated with a significantly worse histologic response (P =.03). In patients presenting with nonmetastatic disease, expression of HER2/erbB-2 at the time of initial biopsy was associated with a significantly decreased event-free survival (47% v 79% at 5 years, P =.05). p53 and p-glycoprotein expression did not correlate with histologic response or patient event-free survival.The correlation of HER2/erbB-2 expression with histologic response to preoperative chemotherapy and event-free survival in this study suggests that HER2/erbB-2 should be evaluated prospectively as a prognostic indicator. The correlation also suggests that clinical trials of antibodies that target this receptor, such as recombinant humanized anti-HER2 monoclonal antibody (Herceptin; Genentech, San Francisco, CA), should be considered for the treatment of osteosarcoma.
Impact of the new AASM 2013 scoring criteria on the prevalence of sleep disordered breathing in the general population
Authors: Sopharat Vat, Jose Haba-Rubio, Daniela Andries, Nadia Tobback, Mehdi Tafti, Heinzer Raphaël
Journal: European Respiratory Journal (2013)

Background:  Rules for scoring sleep disordered breathing (SDB) were recently updated by the American Academy of Sleep Medicine (AASM).   Aims and objectives:  To compare the apnea-hypopnea indexes (AHI) using 3 scoring criteria: AASM 2013 , AASM 2007  and AASM Chicago  and to determine their impact on the prevalence of SDB in the general population.   Methods:  2020 subjects (50% women, 57.3 ± 10.7 years old, BMI 25.5 ± 4.3 kg/m 2 ) participating in an ongoing population-based sleep cohort study (HypnoLaus, Lausanne, Switzerland) underwent complete polysomnographic recordings at home. Hypopnea were first scored according to the Chicago rules. Those associated with a desaturation of ≥4% (AASM  2007 ) or a ≥3% (∼AASM  2013 ) were then selected. Prevalence and severity of SDB were compared.   Results:  AASM 2013 rules yield a higher AHI than AASM 2007  and lower than AASM Chicago  (table 1). For an AHI threshold of ≥5/h, the prevalence of SDB is 63.6% using the AASM 2013  rules and, assuming they represent the gold standard, the AASM 2007  rules would accounts for a 28.3% rate of false-negatives and the AASM Chicago,  for a15.6% rate of false-positives.   Conclusion : The prevalence of SDB in our population is higher than previously reported and varies with the scoring rules. Mean AHI and SDB prevalence using AASM  2013  rules are greater than with AASM 2007  and lower than with AASM Chicago .
Radiolabeled antibodies: another form of cytotoxic treatment.
Authors: R Levy, R A Miller
Journal: Journal of Clinical Oncology (1991)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1991.9.4.537 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2066751 Radiolabeled antibodies: another form of cytotoxic treatment. R LevyxR LevySearch for articles by this author , R A MillerxR A MillerSearch for articles by this author https://doi.org/10.1200/JCO.1991.9.4.537 PDF "Radiolabeled antibodies: another form of cytotoxic treatment.." Journal of Clinical Oncology, 9(4), pp. 537–538© 1991 by American Society of Clinical Oncology
Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure
Authors: Maria Rosa Costanzo, Daniel Negoianu, Brian E. Jaski, Bradley A. Bart, James T. Heywood, Inder S. Anand, James M. Smelser, Alan M. Kaneshige, Don B. Chomsky, Eric D. Adler, Garrie J. Haas, James A. Watts, Jose L. Nabut, Michael P. Schollmeyer, Gregg C. Fonarow
Journal: JACC Heart Failure (2015)
MLL Gene Rearrangement, Cytogenetic 11q23 Abnormalities, and Expression of the NG2 Molecule in Infant Acute Myeloid Leukemia
Authors: Joanne M. Hilden, Franklin O. Smith, Joy L. Frestedt, Ronald McGlennen, William B. Howells, Poul H.B. Sorensen, Diane C. Arthur, William G. Woods, Jonathan Buckley, Irwin D. Bernstein, John H. Kersey
Journal: Blood (1997)
Carbamazepine in the treatment of catatonia
Authors: H W Rankel, L E Rankel
Journal: American Journal of Psychiatry (1988)

Carbamazepine resolved within 6-24 hours the catatonic stupor in two patients, one with a schizophreniform and one with a schizoaffective disorder. Reports of frequent EEG abnormalities and the successful use of diazepam in catatonia prompted these trials with another anticonvulsant.
Abstract 11970: The Impact of First-Fill Discontinuations on Non-Adherence to Antihypertensive Therapy: An Observational Study
Authors: David F Blackburn, Charity D Evans, Dean T Eurich, Alfred J Remillard, Yvonne M Shevchuk
Journal: Circulation (2011)

Background: Medication non-adherence is a barrier to the successful management of hypertension, but little is known about the impact that immediate discontinuations have on antihypertensive (AHT) n...
Abstract 570: N-terminal Pro-brain Natriuretic Peptide And 6-month Mortality In Patients With Preserved Lv Systolic Function After Acute Myocardial Infarction
Authors: Hyeon Min Ryu, Shung Chull Chae, Jang Hoon Lee, Myung Hwan Bae, Yong Seop Kwon, Dong Heon Yang, Hun Sik Park, Yongkeun Cho, Jae-Eun Jun, Wee-Hyun Park
Journal: Circulation (2008)

Background: It has been known that myocardial ischemia augments the synthesis and release of B-type natriuretic peptide (BNP). Although plasma BNP has been shown to provide prognostic information in patients with left ventricular (LV) dysfunction after acute myocardial infarction (AMI), few data are available for the patients with preserved LV systolic function. We investigated 6-month prognostic value of plasma N-terminal pro-BNP (NT-proBNP) in patients with preserved LV systolic function (LV ejection fraction (EF)> 50%) following AMI.  Methods: Between November 2005 and December 2006, 2607 eligible patients (1867 males and 740 females; mean age=63.0 ± 12.3 year-old) were analyzed in the Korea Acute Myocardial Infarction Registry (KAMIR), on-line prospective and observational registration carried out throughout 41 primary percutaneous coronary intervention (PCI) centers. We measured NT-proBNP at admission. The LVEF was measured by 2D echocardiography.  Results: Six-month mortality was 1.8% in patients with preserved LV systolic function after index AMI. Multivariate analysis showed log NT-proBNP (odds ratio [OR] 2.88, 95% confidence interval [CI] 1.14 to 7.26), antecedent diabetes (OR 7.86, 95% CI 2.05 to 30.07), body mass index (OR 0.58, 95% CI 0.39 to 0.86), systolic blood pressure (OR 0.95, 95% CI 0.91 to 0.99) were independent predictor of 6-month mortality after adjustment for age, weight, diastolic blood pressure, Killip class, previous ischemic heart disease, smoking status, PCI, drug therapy, and lipid profiles. Receiver operating characteristic (ROC) curve showed a best cut-off value of NT-proBNP to predict 6-month mortality was 938.5pg/mL with a sensitivity of 73.3% and a specificity of 70.9% (AUC = 0.784, p   Conclusions: Plasma NT-proBNP is an independent predictor of 6-month mortality in patients with preserved LV systolic function following AMI.
Laryngopharyngeal reflux - LPR in selected group from outpatient ENT clinic
Authors: Andrzej Dymek, Lucyna Dymek, Liwia Starczewska-Dymek, Tomasz Dymek
Journal: European Respiratory Journal (2013)

Introduction :Global Consensus Group in Montreal confirmed that chronic laryngitis is a evidence-based related with Gastroesophageal Reflux Disease/GERD/ in 2006.   Aims : Evaluation of frequency LPR in patients suffer from persistent hoarseness.  Assesment of relationships between LPR clinical symptoms - RSI (Reflux Symptom Index), RFS (Reflux Finding Score) and pharyngeal pH - Ryan Score Value.   Materials and methods:   42 patients from the Outpatient ENT with persistent hoarseness and RSI >= 13 - excluding other cofactors: nicotinism, work involving exposure to dust and effort of the voice. In all subjects we have performed wideolaryngoscopical examination and pharyngeal pH monitoring using Dx-pH System Restech™. The control group consisted of 13 healthy volunteers.   Results:  Among 42 patients with persistent hoarseness we have confirmed LPR in 35 patients (83.33%). In 7 subjects pharyngeal pH monitoring excluded LPR. In all patients with LPR we have found only 5 laryngologoscopical changes in larynx among 8 according to RFS. The most frequent inflammatory changes were isolated hyperaemia / erythema of arytenoid and intraarytenoid regions (laryngitis posterior).These findings were confirmed in 30/35 patients with LPR. Median value of RFS in patients with LPR was 4.45 ,lower than the border value for LPR recognition, which is 7. This is statistically significant positive correlation between Ryan score and value in RFS (correlation coefficient 0.91, p   Conclusions:  We have confirmed LPR in 83.33% selected patients with hoarseness based on pharyngeal pH monitoring. RFS value below 7 don9t exclude diagnosis of LPR.  .
Cancer incidence varies widely across England, figures show
Authors: Ingrid Torjesen
Journal: BMJ (2015)

The North West has England’s highest incidence of cancer and London the lowest, the latest data from the Office for National Statistics show.

The average age standardised cancer incidence in England in 2013 was 601 cases per 100 000 people, but there was wide regional variation: the rate was 11.5% higher in the North West than in London.

The North West’s incidence was 636.6 per 100 000. Above average rates were also found in the North East (633.3), Yorkshire and the Humber (616.6), the South West (604.1), and the West Midlands (602.9). London had the lowest incidence of cancer at 571.0 cases per 100 000, followed by the …
Stop smoking services must become “e-cigarette” friendly, says Public Health England
Authors: Ingrid Torjesen
Journal: BMJ (2015)

Stop smoking services should support smokers who choose to quit by using electronic (e) cigarettes even though they are unlicensed products, Public Health England (PHE) has said.

Smokers will not be able to get e-cigarettes on prescription from healthcare professionals or dedicated stop smoking services in the same way as regulated nicotine replacement therapy such as patches and gum, PHE told a press briefing on 18 August. But, as e-cigarettes worked most effectively as a quitting aid when used in a supportive environment, such as that provided by stop smoking services, PHE said that it wanted to encourage this.

“Until we have safe and regulated e-cigarettes we cannot proactively support any specific brand within the health service,” said …
Beyond Cholesterol
Authors: Franklin H. Epstein, Daniel Steinberg, Sampath Parthasarathy, Thomas E. Carew, John C. Khoo, Joseph L. Witztum
Journal: New England Journal of Medicine (1989)

IT is now well established that hypercholesterolemia is an important cause of coronary heart disease, and clinical intervention studies have demonstrated the therapeutic value of correcting hypercholesterolemia.1 , 2 The National Cholesterol Education Program has been instituted on the basis of these findings.3 From that ambitious program we can anticipate the development of progressively better methods of reducing plasma cholesterol levels and therefore even further decreases in mortality from coronary heart disease. However, no matter how successfully we deal with hypercholesterolemia, coronary heart disease will not disappear, because a high cholesterol level is by no means the only causative factor. At any . . .
Effects of topical tretinoin on dysplastic nevi.
Authors: A C Halpern, L M Schuchter, D E Elder, D Guerry, R Elenitsas, B Trock, I Matozzo
Journal: Journal of Clinical Oncology (1994)

PURPOSE As potential precursors of melanoma and markers of increased melanoma risk, dysplastic nevi are suitable targets of strategies for melanoma chemoprevention. We report the results of a pilot study of topical retinoic acid in patients with dysplastic nevi. PATIENTS AND METHODS Five male patients with dysplastic nevi applied tretinoin to half of the back for 6 months. Baseline photographs of dysplastic nevi were compared with posttreatment photographs and assessed for morphologic change. At study completion, each subject had four nevi excised from the treated side and four from the untreated side of the back. Biopsies were histologically evaluated for the presence of dysplasia. RESULTS All patients developed signs of irritation as a result of treatment. One patient was not compliant with treatment due to skin irritation. The four compliant patients showed significant decreases in the clinical atypia of treated lesions, with concomitant fading and even disappearance of many treated nevi. Histologically, only four of 16 treated nevi met histologic criteria for dysplasia, in comparison to 13 of 16 untreated nevi. CONCLUSION These results suggest that there is concomitant clinical and histologic improvement in a significant percentage of dysplastic nevi treated with topical tretinoin. However, the utility of topical tretinoin for chemoprevention of melanoma is limited by difficulty of application and associated inflammation. While new strategies in chemoprevention of melanoma are explored, sun protection and assiduous avoidance of sunburn must remain the mainstay of melanoma prevention.
Review: Brief screening tests for dementia have pooled sensitivity of 76% to 92% and specificity of 81% to 91%
Authors: Eric Larson
Journal: Annals of Internal Medicine (2015)

ACP Journal Club20 October 2015Review: Brief screening tests for dementia have pooled sensitivity of 76% to 92% and specificity of 81% to 91%Eric Larson, MDEric Larson, MDGroup Health Research Institute, Seattle, Washington, USA (E.L.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2015-163-8-010 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationTsoi KK, Chan JY, Hirai HW, Wong SY, Kwok TC.Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med. 2015;Jun 8. [Epub ahead of print]. https://pubmed.ncbi.nlm.nih.gov/26052687Clinical Impact RatingsGIM/FP/GP: Geriatrics: Reference1. Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med. 1989;19:1015-22. [PMID: 2594878] Google Scholar Author, Article, and Disclosure InformationAuthors: Eric Larson, MDAffiliations: Group Health Research Institute, Seattle, Washington, USA (E.L.)This article was published at Annals.org on 6 October 2015. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 20 October 2015Volume 163, Issue 8Page: JC10KeywordsAlzheimer diseaseCognitive impairmentDementiaMini mental state examinationShort term memorySocioeconomic statusSpecificitySystematic reviewsVascular dementiaVisual impairments ePublished: 20 October 2015 Issue Published: 20 October 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features
Authors: Aryeh Fischer, Katerina M. Antoniou, Kevin K. Brown, Jacques Cadranel, Tamera J. Corte, Roland M. du Bois, Joyce S. Lee, Kevin O. Leslie, David A. Lynch, Eric L. Matteson, Marta Mosca, Imre Noth, Luca Richeldi, Mary E. Strek, Jeffrey J. Swigris, Athol U. Wells, Sterling G. West, Harold R. Collard, Vincent Cottin
Journal: European Respiratory Journal (2015)

Many patients with an idiopathic interstitial pneumonia (IIP) have clinical features that suggest an underlying autoimmune process but do not meet established criteria for a connective tissue disease (CTD). Researchers have proposed differing criteria and terms to describe these patients, and lack of consensus over nomenclature and classification limits the ability to conduct prospective studies of a uniform cohort. The “European Respiratory Society/American Thoracic Society Task Force on Undifferentiated Forms of Connective Tissue Disease-associated Interstitial Lung Disease” was formed to create consensus regarding the nomenclature and classification criteria for patients with IIP and features of autoimmunity. The task force proposes the term “interstitial pneumonia with autoimmune features” (IPAF) and offers classification criteria organised around the presence of a combination of features from three domains: a clinical domain consisting of specific extra-thoracic features, a serologic domain consisting of specific autoantibodies, and a morphologic domain consisting of specific chest imaging, histopathologic or pulmonary physiologic features. A designation of IPAF should be used to identify individuals with IIP and features suggestive of, but not definitive for, a CTD. With IPAF, a sound platform has been provided from which to launch the requisite future research investigations of a more uniform cohort.
Mason-Pfizer Monkey Virus Isolated From Spontaneous Mammary Carcinoma of a Female Monkey. I. Detection of Virus Antigens by Immunodiffusion, Immunofluorescent, and Virus Agglutination Techniques&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Mumtaz Ahmed, Sami A. Mayyasi, Harish C. Chopra, Inna Zelljadt, Erlins M. Jensen
Journal: JNCI Journal of the National Cancer Institute (1971)
Aspergillus sensitization is associated with airflow limitation and bronchiectasis in severe asthma
Authors: D. Menzies, L. Holmes, G. McCumesky, C. Prys-Picard, R. Niven
Journal: Allergy (2011)

To cite this article: Menzies D, Holmes L, McCumesky G, Prys-Picard C, Niven R. Aspergillus sensitization is associated with airflow limitation and bronchiectasis in severe asthma. Allergy 2011; 66: 679–685. Background: Abnormalities, including bronchiectasis, that are detectable on high-resolution computed tomography (HRCT) have been associated with severe asthma. Bronchiectasis is associated with the diagnosis of allergic bronchopulmonary aspergillosis (ABPA), which also occurs in patients with severe asthma. We sought to determine the frequency and pattern of HRCT abnormality and the relationship with Aspergillus fumigatus sensitization in one severe asthma population. Methods: We examined our database of patients attending a supraregional severe asthma service (Manchester, UK). Clinical, physiological and immunological characteristics were compared between those with HRCT evidence of airway disease (specifically bronchiectasis) and those with no radiological abnormality. Results: Of 133 patients analysed, 111 (83.4%) had an abnormal HRCT with bronchial wall thickening (41.3%), bronchiectasis (35.3%), air trapping (20.3%) and bronchial dilatation (16.5%) occurring most frequently. Radiological evidence of airway disease was associated with more obstructive spirometry (postbronchodilator FEV1/FVC ratio 73.2%vs 64.8% [difference −8.5%, 95% CI −16.9 to −0.1, P = 0.048]). A. fumigatus sensitization was associated with a 2.01 increased hazard ratio of bronchiectasis (95% CI 1.26 to 3.22, P = 0.005), and more obstructive spirometry (postbronchodilator FEV1/FVC ratio 57.6 vs 70.3 [difference −12.8, 95% CI −19.8 to −5.7, P = 0.001]). Patients with A. fumigatus sensitization had variable clinical and radiological characteristics that frequently did not conform to the conventional diagnostic criteria for ABPA. Conclusion: Patients with severe asthma frequently have radiological abnormalities on HRCT. Sensitization to A. fumigatus is associated with bronchiectasis and greater airflow obstruction, even when diagnostic criteria for ABPA are not met.
Phosphoprotein pathway mapping: AKT/mTOR activation is negatively associated with childhood Rhabdomyosarcoma survival
Authors: Virginia Espina, Benedetta Accordi, Robyn Araujo, Brieanne Midura, Choh Yeung, Xiaolin Wan, Gabriel S. Eichler, Donald J. Johann, William Meyer, Stephen Qualman, James R. Anderson, Seth M. Steinberg, Maria Tsokos, Kartik Krishnan, Emanuel F. Petricoin, Lee J. Helman, Lance A. Liotta
Journal: Clinical Cancer Research (2006)

B72   The elucidation of the kinase-driven signaling pathways within tumors can identify new targets for therapy and provide a means to stratify patients for individualized therapy. Despite advances in combination chemotherapy, the overall survival for childhood rhabdomyosarcoma (RMS) remains approximately 60% .  A critical goal is to identify functionally important protein signaling defects associated with treatment failure for the 40% non-responder cohort. Here we show, by phospho-proteomic network analysis of microdissected tumor cells, that inter-linked components of the Akt/mTOR pathway exhibited increased levels of phosphorylation for tumors of patients with short term survival.Frozen tumor specimens (n=59) were obtained from the Children9s Oncology Group Intergroup Rhabdomyosarcoma Study (IRS) IV, D9502 and D9803, with 12 year clinical follow-up. Reverse phase protein microarrays were used to interrogate the  in vivo  IRS-1/Akt/mTOR phosphoprotein circuits of microdissected childhood Rhabdomyosarcoma samples.High phosphorylation levels were associated with poor overall (OAS) and poor disease-free (DFS) survival (Akt Ser473 (OAS p
Treatment Options Expanding for Advanced Melanoma
Authors: John A. Thompson
Journal: Journal of the National Comprehensive Cancer Network (2015)

Immunotherapies and BRAF and MEK inhibitors have dramatically improved outcomes in advanced melanoma. The availability of these novel approaches has necessitated changes to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). The NCCN Guidelines feature algorithms that aid clinicians in selecting initial therapy, which now includes anti-programmed death protein receptor-1 PD-1 inhibitors among the recommended systemic therapy options for patients with metastatic or unresectable disease.